Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?

Research output: Contribution to journalArticle

Standard

Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease? / Lim, Hoong; Tayebjee, M; Tan, K; Patel, Jeetesh; Macfadyen, Robert; Lip, Gregory.

In: Thrombosis Research, Vol. 122, No. 3, 01.01.2008, p. 307-313.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Lim, Hoong ; Tayebjee, M ; Tan, K ; Patel, Jeetesh ; Macfadyen, Robert ; Lip, Gregory. / Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?. In: Thrombosis Research. 2008 ; Vol. 122, No. 3. pp. 307-313.

Bibtex

@article{4311d51773224677a6394571acbd27f4,
title = "Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?",
abstract = "BACKGROUND: In cardiovascular disease, soluble CD40 ligand (sCD40L) has been associated with an adverse prognosis. Angiogenesis has been implicated in the progression of coronary artery disease (CAD) and sCD40L has pro-angiogenic effects in vitro. Angiogenesis itself is regulated by many mediators, such as vascular endothelial growth factor (VEGF) and the angiopoietins (Ang). Ang-1 promotes vascular maturation whilst Ang-2 destabilises the blood vessel and permits vascular growth with VEGF. Hence, selective elevation of VEGF and Ang-2 suggest a state of vascular plasticity and increased angiogenesis. We hypothesised raised plasma levels of VEGF and Ang-2, but not Ang-1, and correlations with raised sCD40L levels and CAD severity/collateralisation in patients with CAD. METHODS: We recruited 153 patients attending diagnostic angiography for CAD and 47 healthy controls. Patients with previous revascularisation or unequivocally normal angiograms were excluded. The coronary atheroma score (CAS) and coronary stenosis score (CSS), and the presence of collaterals, were assessed by 2 blinded observers. Plasma sCD40L, VEGF, Ang-1 and -2 levels were measured by ELISA. RESULTS: Plasma levels of sCD40L, VEGF and Ang-2, but not Ang-1, were higher in CAD patients compared to controls. Both plasma VEGF (r=0.526, p",
keywords = "angiopoietin, vascular endothelial growth factor, soluble CD40 ligand, atherosclerosis, angiogenesis",
author = "Hoong Lim and M Tayebjee and K Tan and Jeetesh Patel and Robert Macfadyen and Gregory Lip",
year = "2008",
month = jan,
day = "1",
doi = "10.1016/j.thromres.2007.10.013",
language = "English",
volume = "122",
pages = "307--313",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier",
number = "3",

}

RIS

TY - JOUR

T1 - Is soluble CD40 ligand a mediator of angiogenesis in patients with coronary artery disease?

AU - Lim, Hoong

AU - Tayebjee, M

AU - Tan, K

AU - Patel, Jeetesh

AU - Macfadyen, Robert

AU - Lip, Gregory

PY - 2008/1/1

Y1 - 2008/1/1

N2 - BACKGROUND: In cardiovascular disease, soluble CD40 ligand (sCD40L) has been associated with an adverse prognosis. Angiogenesis has been implicated in the progression of coronary artery disease (CAD) and sCD40L has pro-angiogenic effects in vitro. Angiogenesis itself is regulated by many mediators, such as vascular endothelial growth factor (VEGF) and the angiopoietins (Ang). Ang-1 promotes vascular maturation whilst Ang-2 destabilises the blood vessel and permits vascular growth with VEGF. Hence, selective elevation of VEGF and Ang-2 suggest a state of vascular plasticity and increased angiogenesis. We hypothesised raised plasma levels of VEGF and Ang-2, but not Ang-1, and correlations with raised sCD40L levels and CAD severity/collateralisation in patients with CAD. METHODS: We recruited 153 patients attending diagnostic angiography for CAD and 47 healthy controls. Patients with previous revascularisation or unequivocally normal angiograms were excluded. The coronary atheroma score (CAS) and coronary stenosis score (CSS), and the presence of collaterals, were assessed by 2 blinded observers. Plasma sCD40L, VEGF, Ang-1 and -2 levels were measured by ELISA. RESULTS: Plasma levels of sCD40L, VEGF and Ang-2, but not Ang-1, were higher in CAD patients compared to controls. Both plasma VEGF (r=0.526, p

AB - BACKGROUND: In cardiovascular disease, soluble CD40 ligand (sCD40L) has been associated with an adverse prognosis. Angiogenesis has been implicated in the progression of coronary artery disease (CAD) and sCD40L has pro-angiogenic effects in vitro. Angiogenesis itself is regulated by many mediators, such as vascular endothelial growth factor (VEGF) and the angiopoietins (Ang). Ang-1 promotes vascular maturation whilst Ang-2 destabilises the blood vessel and permits vascular growth with VEGF. Hence, selective elevation of VEGF and Ang-2 suggest a state of vascular plasticity and increased angiogenesis. We hypothesised raised plasma levels of VEGF and Ang-2, but not Ang-1, and correlations with raised sCD40L levels and CAD severity/collateralisation in patients with CAD. METHODS: We recruited 153 patients attending diagnostic angiography for CAD and 47 healthy controls. Patients with previous revascularisation or unequivocally normal angiograms were excluded. The coronary atheroma score (CAS) and coronary stenosis score (CSS), and the presence of collaterals, were assessed by 2 blinded observers. Plasma sCD40L, VEGF, Ang-1 and -2 levels were measured by ELISA. RESULTS: Plasma levels of sCD40L, VEGF and Ang-2, but not Ang-1, were higher in CAD patients compared to controls. Both plasma VEGF (r=0.526, p

KW - angiopoietin

KW - vascular endothelial growth factor

KW - soluble CD40 ligand

KW - atherosclerosis

KW - angiogenesis

U2 - 10.1016/j.thromres.2007.10.013

DO - 10.1016/j.thromres.2007.10.013

M3 - Article

C2 - 18054068

VL - 122

SP - 307

EP - 313

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 3

ER -